Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2015

01-02-2015 | Original Article

Novel FTS-diamine/cinnamic acid hybrids inhibit tumor cell proliferation and migration and promote apoptosis via blocking Ras-related signaling in vitro

Authors: Yong Ling, Xinmei Zhao, Xianghua Li, Xuemin Wang, Yang Yang, Zhiqiang Wang, Xinyang Wang, Jie Zhang, Yihua Zhang

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2015

Login to get access

Abstract

Novel FTS-diamine/cinnamic acid hybrids 7a–f were prepared, and their in vitro biological activities were evaluated. It was found that 7c showed the strongest anti-proliferation activities against cancer cells in vitro and significant growth inhibition of tumor in vivo, and more potential for inhibitory selectivity to tumor cells than intermediate 6 and FTS. Furthermore, the anti-proliferative effect of 7c in Lovo cell lines followed a similar pattern, which included a dose-dependent induction of cell apoptosis via the up-regulation of Bax as well as activated caspase-3 and down-regulation of Bcl-2, and the inhibition of cancer cells migration and invasion in a concentration-dependent way. More importantly, 7c could significantly block Ras-related signaling pathways, which may contribute to its pro-apoptotic induction of the cancer cell lines and its inhibition of carcinoma cell proliferation, migration, and invasion. Therefore, our novel findings may provide a new framework for the discovery of new FTS hybrids for the intervention of human carcinoma cells.
Appendix
Available only for authorised users
Literature
1.
2.
Vigil D, Cherfils J, Rossman KL et al (2010) Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy. Nat Rev Cancer 10(12):842–857PubMedCentralPubMedCrossRef
3.
Wang YY, Ren T, Cai YY et al (2013) MicroRNA let-7a inhibits the proliferation and invasion of non-small cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm 28(2):131–137PubMedCrossRef
4.
Zhang JG, Zhao G, Qin Q et al (2013) Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways. Pancreatology 13(2):140–146PubMedCrossRef
5.
6.
Wu KL, Huang EY, Jhu EW et al (2013) Overexpression of galectin-3 enhances migration of colon cancercells related to activation of the K-Ras–Raf–Erk1/2 pathway. J Gastroenterol 48(3):350–359PubMedCrossRef
7.
8.
Wang W, Fang G, Rudolph J (2012) Ras inhibition via direct Ras binding—is there a path forward? Bioorg Med Chem Lett 22(18):5766–5776PubMedCrossRef
9.
Blum R, Cox AD, Kloog Y (2008) Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 3(1):31–47PubMedCrossRef
10.
Riely GJ, Johnson ML, Medinaetal C et al (2011) A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 6(8):1435–1437PubMedCrossRef
11.
12.
McCarthy AL, O’Callaghan YC, Piggott CO et al (2013) Brewers’ spent grain; bioactivity of phenolic component, its role in animal nutrition and potential for incorporation in functional foods: a review. Proc Nutr Soc 72(1):117–125PubMedCrossRef
13.
Serafim TL, Carvalho FS, Marques MP et al (2011) Lipophilic caffeic and ferulic acid derivatives presenting cytotoxicity against human breast cancer cells. Chem Res Toxicol 24(5):763–774PubMedCrossRef
14.
Tsai CM, Yen GC, Sun FM et al (2013) Assessment of the anti-invasion potential and mechannism of select cinnamic acid derivatives on human lung adenocarcinoma. Mol Pharm 10(5):1890–1900PubMedCrossRef
15.
Yuan Z, Zhang JP, Yang C (2012) Study on the effects of ferulic acid on the vascular smooth muscle cell migration in vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi 32(2):229–233PubMed
16.
Welch DR, Harper DE, Yohem KH (1993) U-77,863: a novel cinnanamide isolated from Streptomyces griseoluteus that inhibits cancer invasion and metastasis. Clin Exp Metastasis 11(2):201–212PubMedCrossRef
17.
Tanaka T, Kohno H, Nomura E et al (2003) A novel geranylated derivative, ethyl 3-(4′-geranyloxy-3′-methoxyphenyl)-2-propenoate, synthesized from ferulic acid suppresses carcinogenesis and inducible nitric oxide synthase in rat tongue. Oncology 64(2):166–175PubMedCrossRef
18.
Ling Y, Wang Z, Zhu H et al (2014) Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents. Bioorg Med Chem 22(1):374–380PubMedCrossRef
19.
Hess S, Akermann MA, Wnendt S et al (2001) Synthesis and immunological activity of water-soluble thalidomide prodrugs. Bioorg Med Chem 9(5):1279–1291PubMedCrossRef
20.
21.
Ryu BJ, Lee H, Kim SH et al (2014) PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings. Mol Cell Biochem 389(1–2):69–77PubMedCrossRef
22.
Hannun YA (1997) Apoptosis and the dilemma of cancer chemotherapy. Blood 89(6):1845–1853PubMed
23.
Perfettini JL, Reed JC, Israel N et al (2002) Role of Bcl-2 family members in caspase-independent apoptosis during chlamydia infection. Infect Immun 70(1):55–61PubMedCentralPubMedCrossRef
24.
Harris MH, Thompson CB (2000) The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 7(12):1182–1191PubMedCrossRef
25.
McCubrey JA, Steelman LS, Chappell WH et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773(8):1263–1284PubMedCentralPubMedCrossRef
26.
Goldberg L, Kloog YA (2006) Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 66(24):11709–11717PubMedCrossRef
27.
Fu Z, Smith PC, Zhang L et al (2003) Effects of raf kinase inhibitor protein on suppression of prostate cancer metastasis. J Natl Cancer Inst 95(12):878–889PubMedCrossRef
Metadata
Title
Novel FTS-diamine/cinnamic acid hybrids inhibit tumor cell proliferation and migration and promote apoptosis via blocking Ras-related signaling in vitro
Authors
Yong Ling
Xinmei Zhao
Xianghua Li
Xuemin Wang
Yang Yang
Zhiqiang Wang
Xinyang Wang
Jie Zhang
Yihua Zhang
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2650-2

Other articles of this Issue 2/2015

Cancer Chemotherapy and Pharmacology 2/2015 Go to the issue

Original Article

Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer

Original Article

Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor

Review Article

Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?

Original Article

Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells

Short Communication

Novel in silico-designed estradiol analogues are cytotoxic to a multidrug-resistant cell line at nanomolar concentrations

Original Article

A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits